Facing huge revenue losses as a result of expiring patents for anti-seizure pills, drug makers teamed up with the industry-funded Epilepsy Foundation to press states to suppress generic-drug competition, the Murdoch Wall Street Journal recently reported. The Journal reported that when the foundation’s San Antonio and Houston chapters decided to make such a lobby push in Austin, Abbott Laboratories agreed to fund their efforts.
Read the Lobby Watch
 |
 |
 |
 |
 |
